Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex

Trial Profile

Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Epilepsy
  • Focus First in man; Therapeutic Use
  • Most Recent Events

    • 04 Nov 2016 Results assessing long term efficacy and safety of everolimus over four years published in the Neurology.
    • 19 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 28 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2020 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top